1. Home
  2. XMTR vs ERAS Comparison

XMTR vs ERAS Comparison

Compare XMTR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xometry Inc.

XMTR

Xometry Inc.

HOLD

Current Price

$89.86

Market Cap

4.2B

Sector

Technology

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$18.65

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XMTR
ERAS
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.0B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
XMTR
ERAS
Price
$89.86
$18.65
Analyst Decision
Buy
Strong Buy
Analyst Count
10
12
Target Price
$58.60
$14.25
AVG Volume (30 Days)
734.1K
3.2M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
26.95
36.23
EPS
N/A
N/A
Revenue
$686,631,000.00
N/A
Revenue This Year
$23.76
N/A
Revenue Next Year
$18.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.87
N/A
52 Week Low
$35.86
$1.33
52 Week High
$106.08
$24.28

Technical Indicators

Market Signals
Indicator
XMTR
ERAS
Relative Strength Index (RSI) 48.57 53.18
Support Level $88.52 $17.36
Resistance Level $98.55 $19.96
Average True Range (ATR) 4.56 0.99
MACD 0.42 -0.12
Stochastic Oscillator 56.12 67.76

Price Performance

Historical Comparison
XMTR
ERAS

About XMTR Xometry Inc.

Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: